子宫颈抹片检查的全球市场:现状分析与预测(2022年～2028年)

全球子宫颈抹片检查市场，由于子宫颈癌症患者的剧增，技术开拓，癌症诊察计划增加，预计稳定成长约11.4％。在全球子宫颈癌症剧增，成为促进该市场成长的主要原因。

本报告提供全球子宫颈抹片检查市场相关调查分析，市场概要，各市场区隔、各地区的市场分析，市场成长的影响因素，市场趋势，竞争情形，主要企业简介等彙整资讯。

目录

第1章 市场简介

第2章 调查手法、前提

第3章 市场概要

第4章 摘要整理

第5章 COVID-19对子宫颈抹片检查市场的影响

第6章 子宫颈抹片检查市场收益(2020年～2028年)

第7章 市场洞察:各方法

• 液体为基础
• 传统为基础

第8章 市场洞察:各试验类型

• 巴氏涂片
• 一次HPV筛检
• 共同试验
• HPV的追踪检验

第9章 市场洞察:各用途

• 子宫颈癌症诊察
• 阴道癌症诊察
• 其他

第10章 市场洞察:各产品

• 器具
• 消耗品
• 其他

第11章 市场洞察:各技术

• PCR
• 其他

第12章 市场洞察:各终端用户

• 研究所
• 诊断中心
• 医院、诊疗所
• 其他

第13章 市场洞察:各地区

• 北美
  • 美国
  • 加拿大
  • 其他北美
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 全球其他地区

第14章 子宫颈抹片检查的市场动态

• 推动市场要素
• 市场课题

第15章 子宫颈抹片检查的市场机会

第16章 子宫颈抹片检查的市场趋势

第17章 需求侧、供给侧的分析

• 需求面分析
• 供给侧分析

第18章 价值链分析

第19章 竞争模式

• 竞争情形
  • 波特的五力分析

第20章 公司概要

• Abbott
• F. Hoffmann-La Roche Ltd.
• BD
• QIAGEN
• Thermo Fisher Scientific Inc.
• HOLOGIC, INC.
• Seegene Inc.
• Arbor Vita Corporation
• Femasys Inc.
• Hospital Equipment Mfg. Co.

第21章 免责声明

The human papillomavirus (HPV) family is made up of 150 or so closely related viruses. The human papillomavirus is divided into different types and numbers. Only particular cell types known as squamous epithelial cells are attracted to the human papillomavirus, and these cells are also the only ones where the virus can thrive. An accurate screening method to ascertain if cervical cells are abnormal or normal is the pap test. Commonly known as a pap smear is a treatment used to check women for cervical cancers. A pap smear can also identify alterations in cervical cells that point to the potential emergence of cancer. People who have abnormal pap test results are encouraged to get a human papillomavirus test to further assess their risk of cervical cancer.

The Pap Test Market is expected to grow at a steady rate of around 11.4% owing to a surge in the cases of cervical cancers, technological developments taking place, and a rise in the number of cancer screening programs. The surge in the prevalence of cervical cancers among the global population is the major factor responsible for thriving the growth of the market. For instance, according to the World Health Organization, 2021, cervical cancer is the world's fourth-most common cancer, with more than 500,000 cases diagnosed every year.

Based on the method, the market is segmented into liquid-based and conventional-based. The liquid-based segment held a dominant share of the market in 2021. The major reason for the growth in this segment is attributed to the advantages that are offered by these methods. Liquid-based methods have been developed to improve the diagnostic reliability of Papanicolaou (Pap) smears. Traditional methods such as conventional pap smears used to have false-negative and false-positive results owing to inefficient sampling and slide preparation, and errors in laboratory detection and interpretation. Liquid-based methods rinse cervical cells in preservatives so that blood and other potentially obscuring material can be easily separated. It also allows for additional testing of the sample, such as HPV, leading to the growth of the pap test market.

On the basis of application, the market is segmented into cervical cancer screening, vaginal cancer screening, and others. The cervical cancer screening category is expected to hold a major market share during the forecast period owing to the rise in the number of cases of cervical cancers worldwide and the rising need for their diagnosis using pap tests. Moreover, rising initiatives and accurate screening programs are now being implemented so that every woman with cervical disease gets the treatment she needs. WHO's global strategy for cervical cancer elimination- endorsed by the World Health Assembly in 2020 - requires 70% of women globally to be screened regularly for cervical disease with a high-performance test, and 90% of those needing it to receive appropriate treatment. Thus, the above-mentioned factors are the significant factor driving the segmental growth during the forecast period.

On the basis of technology, the market is bifurcated into PCR and others. The others held a dominant share of the market in 2021. The others segment consists of colposcopy and ELISA techniques among others. The dominant share is mainly due to the high adoption rate for colposcopy examinations done for the determination of cervical cancers.

For a better understanding of the market adoption of the pap test, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to dominate the global pap test market mainly due to a surge in the cases of cervical cancers, leading to the need for rising awareness related to early screening for cancers, and various initiatives brought in during the forecast period. For instance, in 2020, WHO launched the Global Strategy to Accelerate the Elimination of Cervical Cancer, which outlined three key steps: vaccination, screening, and treatment. Successful implementation of all three reduced more than 40% of new cases of the disease and 5 million related deaths by 2050. Thus, these factors are driving the regional market in the forecast period.

Some of the major players operating in the market include: Abbott, F. Hoffmann-La Roche Ltd., BD, QIAGEN, Thermo Fisher Scientific Inc., HOLOGIC, INC., Seegene Inc., Arbor Vita Corporation, Femasys Inc., Hospital Equipment Mfg. Co., among others.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Pap Test Market
• 2.2. Research Methodology of the Pap Test Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE PAP TEST MARKET

6 PAP TEST MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY METHOD

• 7.1. Liquid-based
• 7.2. Conventional-based

8 MARKET INSIGHTS BY TEST TYPE

• 8.1. Pap Smear
• 8.2. Primary HPV Screening
• 8.3. Co-Testing
• 8.4. Follow-Up Test for HPV

9 MARKET INSIGHTS BY APPLICATION

• 9.1. Cervical Cancer Screening
• 9.2. Vaginal Cancer Screening
• 9.3. Others

10 MARKET INSIGHTS BY PRODUCT

• 10.1. Instruments
• 10.2. Consumables
• 10.3. Others

11 MARKET INSIGHTS BY TECHNOLOGY

• 11.1. PCR
• 11.2. Others

12 MARKET INSIGHTS BY END-USER

• 12.1. Research Laboratories
• 12.2. Diagnostic Centers
• 12.3. Hospitals & Clinics
• 12.4. Others

13 MARKET INSIGHTS BY REGION

• 13.1. North America
  • 13.1.1. U.S.
  • 13.1.2. Canada
  • 13.1.3. Rest of North America
• 13.2. Europe
  • 13.2.1. Germany
  • 13.2.2. U.K.
  • 13.2.3. France
  • 13.2.4. Italy
  • 13.2.5. Spain
  • 13.2.6. Rest of Europe
• 13.3. Asia-Pacific
  • 13.3.1. China
  • 13.3.2. Japan
  • 13.3.3. India
  • 13.3.4. Rest of Asia-Pacific
• 13.4. Rest of World

14 PAP TEST MARKET DYNAMICS

• 14.1. Market Drivers
• 14.2. Market Challenges

15 PAP TEST MARKET OPPORTUNITIES

16 PAP TEST MARKET TRENDS

17 DEMAND AND SUPPLY-SIDE ANALYSIS

• 17.1. Demand Side Analysis
• 17.2. Supply Side Analysis

18 VALUE CHAIN ANALYSIS

19 COMPETITIVE SCENARIO

• 19.1. Competitive Landscape
  • 19.1.1. Porters Fiver Forces Analysis

20 COMPANY PROFILED

• 20.1. Abbott
• 20.2. F. Hoffmann-La Roche Ltd.
• 20.3. BD
• 20.4. QIAGEN
• 20.5. Thermo Fisher Scientific Inc.
• 20.6. HOLOGIC, INC.
• 20.7. Seegene Inc.
• 20.8. Arbor Vita Corporation
• 20.9. Femasys Inc.
• 20.10. Hospital Equipment Mfg. Co.

21 DISCLAIMER